Abstract: VR was more frequent with < or = 5 baseline NRTI mutations (P = 0.12) or < 4 thymidine-associated mutations (TAMs) without E44D or V118I (P = 0.08).
Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy.
Abstract: BACKGROUND: The V118I mutation is included in the nucleoside analogue mutations (NAMs) set.
Abstract: CONCLUSIONS: The analysis of our observational database suggests that the onset of the V118I mutation after treatment failure is unfavourable for the patient and can be considered a strong marker of disease progression.
Abstract: In univariate analysis, the V118I mutation was significantly associated with a higher HIV RNA level, lower CD4+ T-cell count, Centers for Disease Control and Prevention (CDC) stage C, higher number of pre-GRT regimens and class-wide resistance (CWR) to NRTIs, protease inhibitors and nonnucleoside reverse transcriptase inhibitors.
Abstract: RESULTS: Of the 792 patients included, 114 (14.4%) carried the PMID: 17209775
2006
AIDS research and human retroviruses
Abstract: Most of the RT sequences were wild-type, although V118I (8.5%) and Y318F (5.7%) associated with resistance to lamivudine and nevirapine, respectively, were observed.
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso.
Abstract: Among 17 non-highly active antiretroviral therapy (HAART) patients, 3/17 (17.64%) presented virus with reverse transcriptase (RT) mutations [V118I: 1/17 patients (5.88%), V179E: 2/17 patients (11.76%)].
Diversity of HIV in rural Burkina Faso.
PMID: 16951652
2006
Journal of acquired immune deficiency syndromes (1999)
Abstract: Analysis of drug resistance-associated polymorphisms detected the nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations K103N/E and V118I in 1 individual each, suggesting transmission of drug-resistant viruses or prior use of antiretroviral drugs.
Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response.
PMID: 16910833
2006
AIDS research and human retroviruses
Abstract: Six of 35 (17%) individuals harbored primary mutations for RT inhibitors, including M41L, V118I, Y188H, P236L, and Y318F, and curiously three of the six were infected with CRF06_cpx.
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
PMID: 16870771
2006
Antimicrobial agents and chemotherapy
Abstract: Rather, four mutations (M41L, A62T/V, V118I, and M184V) known to cause resistance to NRTIs and two additional novel mutations (S68N and G112S) adjacent to the catalytic site of the enzyme were selected.
Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
Abstract: CONCLUSION: Different combinations of V118I, H208Y, and T215Y produce NNRTI hypersusceptibility.
Abstract: In addition, H208Y/T215Y, V118I/T215Y, and V118I/H208Y/T215Y were hypersusceptible to delavirdine and nevirapine.
Abstract: RESULTS: The single mutations V118I, H208Y, and T215Y did not show hypersusceptibility to efavirenz with mean fold-change of 0.58, 0.55, and 0.70, respectively (P < 0.01 and P = 0.12).
Abstract: The genetic basis for PMID: 16540937
2006
Journal of acquired immune deficiency syndromes (1999)
Abstract: An increased genetic barrier was calculated for I82A (subtypes C and G), V108I (subtype G), V118I (subtype G), Q151M (subtypes D and F), L210W (subtypes C, F, G, and CRF02_AG), and P225H (subtype A) (P < 0.001 compared with subtype B).
[Primary resistance to antiretroviral therapy in patients with HIV/AIDS in Chile].
HIV mutation literature information.
PMID: 
2007
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT